GLP-1 and arterial inflammation — March 2026

I've been tracking inflammatory markers closely in my patients on GLP-1 receptor agonists, and I want to share a particularly striking case (with patient permission) alongside the broader data.

Patient: 58F, BMI 39.4, T2DM (A1C 8.1%), hypertension, on atorvastatin 40mg. Started semaglutide 2.4 mg. Inflammatory panel over 14 months:

The hsCRP reduction from 8.4 to 0.6 mg/L represents a 93% decline. This patient went from the highest cardiovascular risk category to the lowest based on hsCRP alone.

"In the SELECT trial, semaglutide reduced hsCRP by approximately 38% from baseline, with greater reductions observed in patients with higher baseline levels."^[1]

The question I keep wrestling with: how much of the CV benefit we saw in SELECT is mediated by this anti-inflammatory effect?

^[1] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.

This is a fantastic dataset. The concordance across multiple inflammatory markers (CRP, IL-6, TNF-α, fibrinogen, ferritin) argues strongly against a spurious single-marker finding. This is genuine systemic inflammation resolution.

To your question about mediation: the CANTOS trial provides an important framework. Canakinumab (anti-IL-1β monoclonal antibody) reduced hsCRP by ~35% and MACE by 15% (HR 0.85 for the 150mg dose) without affecting lipids at all.^[1] This proved that inflammation is a causal pathway in atherosclerosis, not just a marker.

In SELECT's mediation analyses, hsCRP reduction explained approximately 28% of the MACE benefit — more than weight loss, more than any single metabolic parameter. The remaining benefit likely comes from:

• Direct anti-atherosclerotic effects (reduced monocyte adhesion, improved endothelial function)
• Reduced visceral adiposity (the primary source of IL-6 and TNF-α)
• Improved hepatic steatosis (the liver is a major CRP producer)

^[1] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377(12):1119-1131.

My hsCRP story isn't as dramatic but still notable. Started at 5.2 mg/L with a BMI of 33 and prediabetes. After 9 months on semaglutide 1.7 mg (insurance won't cover 2.4):

• hsCRP: 5.2 → 1.8 mg/L (65% reduction)
• A1C: 6.3% → 5.4%
• Weight: 218 → 186 lbs

What I find interesting is that my hsCRP plateaued at 1.8 for the past 3 months despite continued slow weight loss. Is there a floor effect, or would going to 2.4 mg push it lower?

There may be a physiological floor for hsCRP reduction depending on the underlying inflammatory milieu. An hsCRP of 1.8 mg/L puts you in the "moderate risk" category and represents a very meaningful improvement from 5.2.

Several factors can maintain residual inflammation even with weight loss and GLP-1 therapy:

• Remaining visceral adipose tissue (even at a normal BMI, visceral fat distribution matters)
• Gut microbiome composition (persistent dysbiosis can drive low-grade endotoxemia)
• Sleep quality (sleep disruption increases IL-6 and CRP)
• Chronic stress (cortisol-inflammation axis)
• Periodontal disease (often overlooked contributor to systemic CRP elevation)

Before escalating the semaglutide dose, I'd investigate these modifiable factors. Dental health is one I've seen make a surprising difference — treating periodontitis can drop hsCRP by 0.5-1.0 mg/L.

To add population-level context on CRP reduction across the GLP-1 trials:

Higher baseline CRP predicts greater absolute (but not always percentage) reductions. The patient in the OP's case with a baseline of 8.4 mg/L was starting from a markedly inflammatory state, which likely explains the dramatic absolute decline.

For reference, each doubling of hsCRP is associated with an approximately 1.4-fold increase in MACE risk. Going from 8.4 to 0.6 represents a massive shift in predicted risk.